OKAY
833230
CHANGFU CO.,LTD
871396
CHENGUANG MEDICAL
430300
Gansu Longshenrongfa Pharmaceutical Industry
300534
Tibet Duo Rui Pharmaceutical
301075
CN Stock MarketDetailed Quotes
000795 Innuovo Technology
- 10.84
- +0.23+2.17%
Noon Break Apr 1 11:30 CST
12.29BMarket Cap49.72P/E (TTM)
10.91High10.63Low162.35KlotVolume10.65Open10.61Pre Close175.01MTurnover1.43%Turnover Ratio49.72P/E (Static)1.13BShares15.8852wk High4.57P/B12.29BFloat Cap5.0652wk Low11.67Limit Up1.13BShs Float15.88Historical High9.55Limit Down2.64%Amplitude0.92Historical Low0.03Dividend TTM10.78Avg Price64.48KlotAsk0.25%Div YieldTTM100Lot Size96.91KlotBid
Innuovo Technology Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -0.67%4.01B | 1.88%2.87B | 3.57%1.94B | 1.67%857.02M | -14.72%4.04B | -20.81%2.81B | -17.88%1.87B | -18.31%842.95M | 25.85%4.73B | 36.71%3.55B |
| Operating revenue | -0.67%4.01B | 1.88%2.87B | 3.57%1.94B | 1.67%857.02M | -14.72%4.04B | -20.81%2.81B | -17.88%1.87B | -18.31%842.95M | 25.85%4.73B | 36.71%3.55B |
| Other operating revenue | -35.09%168.76M | ---- | 2.88%94.43M | ---- | 16.84%259.99M | ---- | -63.68%91.79M | ---- | 76.82%222.52M | ---- |
| Total operating cost | -3.02%3.69B | -2.61%2.64B | -0.26%1.79B | -2.15%792.45M | -13.86%3.8B | -17.92%2.71B | -16.04%1.8B | -17.50%809.89M | 20.51%4.42B | 32.66%3.3B |
| Operating cost | -4.13%3.18B | -1.96%2.3B | 1.00%1.57B | -0.38%681.97M | -14.31%3.32B | -19.13%2.35B | -16.65%1.56B | -18.73%684.55M | 21.94%3.87B | 35.78%2.9B |
| Operating tax surcharges | 18.73%20.04M | 11.27%14.44M | 17.67%9.33M | 31.76%4.6M | -4.95%16.88M | 6.91%12.98M | -0.56%7.93M | -19.67%3.49M | 5.68%17.76M | 2.18%12.14M |
| Operating expense | 2.88%102.89M | -25.93%60.64M | -20.29%38.04M | -12.91%18.38M | -12.76%100.02M | 13.95%81.86M | 4.15%47.72M | -27.00%21.1M | 33.18%114.64M | -1.35%71.84M |
| Administration expense | 18.15%227.9M | 18.18%142.19M | 18.36%95.3M | 18.63%48.16M | -5.24%192.9M | -20.22%120.31M | -23.90%80.52M | -13.78%40.59M | 5.94%203.57M | 23.26%150.8M |
| Financial expense | -114.31%-35.49M | -693.87%-13.86M | -553.19%-14.33M | -134.07%-2.69M | -29.29%-16.56M | 131.22%2.33M | -287.78%-2.19M | 16.37%7.88M | -155.82%-12.81M | -179.03%-7.48M |
| -Interest expense (Financial expense) | -57.29%15.94M | -63.43%9.87M | -62.72%7.21M | -43.27%3.98M | -2.68%37.32M | -27.31%26.98M | -18.00%19.33M | -3.26%7.01M | 81.20%38.35M | 82.97%37.12M |
| -Interest Income (Financial expense) | 38.30%-29.34M | 19.77%-13.65M | 16.91%-7.22M | 91.17%-558.13K | -162.32%-47.55M | -0.36%-17.01M | 12.25%-8.69M | -66.25%-6.32M | 19.84%-18.13M | 5.18%-16.95M |
| Research and development | 0.09%194.88M | -7.32%136.04M | -13.65%92.07M | -19.59%42.04M | -12.70%194.71M | -15.49%146.78M | -4.96%106.63M | 0.07%52.28M | 29.09%223.03M | 27.72%173.68M |
| Credit Impairment Loss | -121.14%-964.57K | -232.45%-2.66M | -407.45%-2.95M | 100.92%22.79K | 227.57%4.56M | 114.32%2.01M | 105.66%959.99K | 60.99%-2.47M | 65.00%-3.58M | -130.42%-14.03M |
| Asset Impairment Loss | 2.93%-115.74M | 61.61%-20.41M | 96.93%-1.16M | 164.09%1.39M | -27.70%-119.23M | 16.83%-53.17M | -21.01%-37.76M | 108.98%526.3K | -293.11%-93.37M | -1,776.50%-63.93M |
| Other net revenue | 61.24%-46.54M | 6.15%18.87M | 717.85%29.44M | 8.12%12.92M | -151.85%-120.08M | 153.86%17.78M | 128.64%3.6M | 38.78%11.95M | -203.60%-47.68M | -194.95%-33.01M |
| Fair value change income | ---- | ---- | ---- | ---- | -370.69%-2.68M | 71.14%-2.69M | 80.13%-1.98M | -33.49%-1.83M | 58.32%990.72K | -229.06%-9.32M |
| Invest income | 108.96%8.87M | -65.95%6.64M | -69.54%4.29M | -96.47%204.82K | -1,245.67%-99M | 511.80%19.49M | 135.75%14.08M | 10.40%5.8M | -125.42%-7.36M | -130.63%-4.73M |
| -Including: Investment income associates | -66.05%20.18K | 649.24%20.18K | 385.88%10.5K | ---- | -2.79%59.44K | 55.30%-3.67K | 55.30%-3.67K | ---- | 767.92%61.15K | 41.79%-8.22K |
| Asset deal income | -65.07%2.26M | -59.43%2.26M | 308.49%2.51M | 149.67%4.73K | 2,823.95%6.48M | 4,177.34%5.57M | 303.19%615.17K | -101.12%-9.53K | -106.31%-237.85K | -104.10%-136.56K |
| Other revenue | -34.25%59.03M | -29.03%33.05M | -3.40%26.75M | 13.74%11.3M | 60.70%89.79M | -21.26%46.57M | -30.61%27.69M | -38.19%9.93M | 19.74%55.87M | 108.87%59.14M |
| Operating profit | 143.94%273.48M | 102.28%246.57M | 123.73%175.67M | 72.18%77.49M | -58.33%112.11M | -44.30%121.9M | -37.99%78.52M | -23.55%45.01M | 89.26%269.04M | 50.58%218.85M |
| Add:Non operating Income | -71.68%1.15M | 102.51%938.16K | 10.56%413.27K | -54.07%135.4K | 462.91%4.07M | -31.75%463.26K | 20.28%373.78K | 11.36%294.8K | -16.30%722.32K | -1.57%678.8K |
| Less:Non operating expense | -11.26%4.23M | -78.70%571K | -4.47%524.9K | -72.67%143.27K | 198.29%4.77M | 140.51%2.68M | -35.41%549.49K | 73.28%524.27K | -87.78%1.6M | 23,958.49%1.11M |
| Total profit | 142.72%270.39M | 106.33%246.94M | 124.09%175.56M | 73.04%77.48M | -58.46%111.4M | -45.20%119.68M | -37.86%78.34M | -23.89%44.78M | 106.40%268.17M | 49.58%218.41M |
| Less:Income tax cost | 39.80%22.85M | 33.67%41.39M | 54.17%32.64M | 54.69%11.49M | -38.64%16.35M | 8.77%30.96M | 31.65%21.17M | 15.30%7.43M | -16.78%26.64M | 114.70%28.47M |
| Net profit | 160.41%247.54M | 131.69%205.55M | 149.98%142.92M | 76.69%65.99M | -60.64%95.06M | -53.29%88.72M | -48.02%57.17M | -28.70%37.35M | 146.66%241.53M | 43.08%189.95M |
| Net profit from continuing operation | 160.41%247.54M | 131.69%205.55M | 149.98%142.92M | 76.69%65.99M | -60.64%95.06M | -53.29%88.72M | -48.02%57.17M | -28.70%37.35M | 146.66%241.53M | 43.08%189.95M |
| Less:Minority Profit | -101.89%-104.19K | -114.60%-938.69K | -458.46%-2.72M | -26.01%-1.78M | 132.32%5.5M | 130.49%6.43M | 104.72%758.45K | 69.43%-1.41M | 54.64%-17.01M | -91.43%-21.09M |
| Net profit of parent company owners | 176.52%247.65M | 150.93%206.49M | 158.16%145.64M | 74.84%67.77M | -65.36%89.56M | -61.01%82.29M | -55.26%56.41M | -32.00%38.76M | 90.91%258.54M | 46.78%211.03M |
| Earning per share | ||||||||||
| Basic earning per share | 179.05%0.2238 | 153.13%0.1863 | 159.01%0.1308 | 75.43%0.0607 | -64.93%0.0802 | -60.45%0.0736 | -54.59%0.0505 | -31.21%0.0346 | 91.38%0.2287 | 46.77%0.1861 |
| Diluted earning per share | 179.05%0.2238 | 153.13%0.1863 | 159.01%0.1308 | 75.43%0.0607 | -64.93%0.0802 | -60.45%0.0736 | -54.59%0.0505 | -31.21%0.0346 | 91.38%0.2287 | 46.77%0.1861 |
| Other composite income | -592.34%-677.82K | -400.01K | -557.83K | -632.85K | 137.67K | |||||
| Other composite income of parent company owners | -592.34%-576.15K | ---340.01K | ---474.15K | ---537.92K | --117.02K | ---- | ---- | ---- | ---- | ---- |
| Other composite income of minority owners | -592.34%-101.67K | ---60K | ---83.67K | ---94.93K | --20.65K | ---- | ---- | ---- | ---- | ---- |
| Total composite income | 159.32%246.87M | 131.24%205.15M | 149.00%142.36M | 74.99%65.36M | -60.59%95.2M | -53.29%88.72M | -48.02%57.17M | -28.70%37.35M | 146.66%241.53M | 43.08%189.95M |
| Total composite income of parent company owners | 175.52%247.07M | 150.52%206.15M | 157.32%145.16M | 73.46%67.23M | -65.31%89.68M | -61.01%82.29M | -55.26%56.41M | -32.00%38.76M | 90.91%258.54M | 46.78%211.03M |
| Total composite income of minority owners | -103.73%-205.86K | -115.53%-998.69K | -469.50%-2.8M | -32.74%-1.87M | 132.44%5.52M | 130.49%6.43M | 104.72%758.45K | 69.43%-1.41M | 54.64%-17.01M | -91.43%-21.09M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Hexin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
